Literature DB >> 23518346

R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.

Dan Ye1, Shenghong Ma, Yue Xiong, Kun-Liang Guan.   

Abstract

The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG). A recent study now shows that R-2-HG can reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential of targeting mutant IDH1 and IDH2.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID： 23518346      PMCID： PMC3652525          DOI： 10.1016/j.ccr.2013.03.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

2.  Expanding chemical biology of 2-oxoglutarate oxygenases.

Authors:  Christoph Loenarz; Christopher J Schofield
Journal:  Nat Chem Biol       Date:  2008-03       Impact factor: 15.040

3.  The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.

Authors:  Rasheduzzaman Chowdhury; Kar Kheng Yeoh; Ya-Min Tian; Lars Hillringhaus; Eleanor A Bagg; Nathan R Rose; Ivanhoe K H Leung; Xuan S Li; Esther C Y Woon; Ming Yang; Michael A McDonough; Oliver N King; Ian J Clifton; Robert J Klose; Timothy D W Claridge; Peter J Ratcliffe; Christopher J Schofield; Akane Kawamura
Journal:  EMBO Rep       Date:  2011-04-01       Impact factor: 8.807

4.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.

Authors:  Masato Sasaki; Christiane B Knobbe; Joshua C Munger; Evan F Lind; Dirk Brenner; Anne Brüstle; Isaac S Harris; Roxanne Holmes; Andrew Wakeham; Jillian Haight; Annick You-Ten; Wanda Y Li; Stefanie Schalm; Shinsan M Su; Carl Virtanen; Guido Reifenberger; Pamela S Ohashi; Dwayne L Barber; Maria E Figueroa; Ari Melnick; Juan-Carlos Zúñiga-Pflücker; Tak W Mak
Journal:  Nature       Date:  2012-08-30       Impact factor: 49.962

5.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

6.  Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Authors:  Peppi Koivunen; Sungwoo Lee; Christopher G Duncan; Giselle Lopez; Gang Lu; Shakti Ramkissoon; Julie A Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan Looper; Keith L Ligon; Roel G W Verhaak; Hai Yan; William G Kaelin
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

7.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

8.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

9.  Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.

Authors:  Mengtao Xiao; Hui Yang; Wei Xu; Shenghong Ma; Huaipeng Lin; Honguang Zhu; Lixia Liu; Ying Liu; Chen Yang; Yanhui Xu; Shimin Zhao; Dan Ye; Yue Xiong; Kun-Liang Guan
Journal:  Genes Dev       Date:  2012-06-07       Impact factor: 12.890

10.  (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.

Authors:  Julie-Aurore Losman; Ryan E Looper; Peppi Koivunen; Sungwoo Lee; Rebekka K Schneider; Christine McMahon; Glenn S Cowley; David E Root; Benjamin L Ebert; William G Kaelin
Journal:  Science       Date:  2013-02-07       Impact factor: 47.728
  10 in total
  36 in total

1.  α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming.

Authors:  Pu-Ste Liu; Haiping Wang; Xiaoyun Li; Tung Chao; Tony Teav; Stefan Christen; Giusy Di Conza; Wan-Chen Cheng; Chih-Hung Chou; Magdalena Vavakova; Charlotte Muret; Koen Debackere; Massimiliano Mazzone; Hsien-Da Huang; Sarah-Maria Fendt; Julijana Ivanisevic; Ping-Chih Ho
Journal:  Nat Immunol       Date:  2017-07-17       Impact factor: 25.606

2.  Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E.

Authors:  Ying Zhang; Stefan Pusch; James Innes; Kastytis Sidlauskas; Matthew Ellis; Joanne Lau; Tedani El-Hassan; Natasha Aley; Francesca Launchbury; Angela Richard-Loendt; Jasper deBoer; Sheng Chen; Lei Wang; Andreas von Deimling; Ningning Li; Sebastian Brandner
Journal:  Cancer Res       Date:  2019-08-07       Impact factor: 12.701

Review 3.  Mutant DNA methylation regulators endow hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse.

Authors:  Yuting Tan; Han Liu; Saijuan Chen
Journal:  Front Med       Date:  2015-12       Impact factor: 4.592

4.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

5.  New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.

Authors:  Ujunwa C Okoye-Okafor; Boris Bartholdy; Jessy Cartier; Enoch N Gao; Beth Pietrak; Alan R Rendina; Cynthia Rominger; Chad Quinn; Angela Smallwood; Kenneth J Wiggall; Alexander J Reif; Stanley J Schmidt; Hongwei Qi; Huizhen Zhao; Gerard Joberty; Maria Faelth-Savitski; Marcus Bantscheff; Gerard Drewes; Chaya Duraiswami; Pat Brady; Arthur Groy; Swathi-Rao Narayanagari; Iléana Antony-Debre; Kelly Mitchell; Heng Rui Wang; Yun-Ruei Kao; Maximilian Christopeit; Luis Carvajal; Laura Barreyro; Elisabeth Paietta; Hideki Makishima; Britta Will; Nestor Concha; Nicholas D Adams; Benjamin Schwartz; Michael T McCabe; Jaroslav Maciejewski; Amit Verma; Ulrich Steidl
Journal:  Nat Chem Biol       Date:  2015-10-05       Impact factor: 15.040

6.  L2hgdh Deficiency Accumulates l-2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration.

Authors:  Shenghong Ma; Renqiang Sun; Bowen Jiang; Jun Gao; Wanglong Deng; Peng Liu; Ruoyu He; Jing Cui; Minbiao Ji; Wei Yi; Pengyuan Yang; Xiaohui Wu; Yue Xiong; Zilong Qiu; Dan Ye; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2017-03-31       Impact factor: 4.272

Review 7.  Epigenetic regulation of cancer stem cell and tumorigenesis.

Authors:  Kezhou Zhu; Victoria Xie; Suyun Huang
Journal:  Adv Cancer Res       Date:  2020-07-16       Impact factor: 6.242

Review 8.  Connections between TET proteins and aberrant DNA modification in cancer.

Authors:  Yun Huang; Anjana Rao
Journal:  Trends Genet       Date:  2014-08-14       Impact factor: 11.639

9.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Authors:  Jie Sun; Xin He; Yinghui Zhu; Zonghui Ding; Haojie Dong; Yimei Feng; Juan Du; Hanying Wang; Xiwei Wu; Lei Zhang; Xiaochun Yu; Allen Lin; Tinisha McDonald; Dandan Zhao; Herman Wu; Wei-Kai Hua; Bin Zhang; Lifeng Feng; Kaoru Tohyama; Ravi Bhatia; Philipp Oberdoerffer; Yang Jo Chung; Peter D Aplan; Jacqueline Boultwood; Andrea Pellagatti; Samer Khaled; Marcin Kortylewski; Flavia Pichiorri; Ya-Huei Kuo; Nadia Carlesso; Guido Marcucci; Hongchuan Jin; Ling Li
Journal:  Cell Stem Cell       Date:  2018-08-23       Impact factor: 24.633

Review 10.  Cancer metabolism: a therapeutic perspective.

Authors:  Ubaldo E Martinez-Outschoorn; Maria Peiris-Pagés; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.